Emerging therapeutic targets in the eradication of Helicobacter pylori

Bibliography

• WARREN JR, MARSHALL BJ: Unidentified curved bacillus on gastric epithelium in chronic active gastritis. Lancet (1983) 1:1273–1275.
   PubMed Web of Science ®Google Scholar
• NIH CONSENSUS CONFERENCE: Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA (1994) 272:65–69.
   PubMed Web of Science ®Google Scholar
• IARC WORKING GROUP ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS: Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr. Eval. Carcinog. Risks Hum. (1994) 61:1–241.
   PubMedGoogle Scholar
• TOMB JF, WHITE O, KERLAVAGE AR et al.: The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature (1997) 388:539–547.
   Google Scholar
• RAUWS EJ, TYTGAT GN: Helicobacter pylori in duodenal and gastric ulcer disease. Baillieres Clin. Gastroenterol. (1995) 9:529–547.
   PubMed Web of Science ®Google Scholar
• SMIT MJ, LEURS R, ALEWIJNSE AE et al.: Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors. Proc. Natl. Acad. Sci. USA (1996) 93:6802–6807.
   PubMed Web of Science ®Google Scholar
• IVANOV C, PETKOV O, PETROV P et al.: Synthesis, gastroprotective, antisecretory and anti-Helicobacter effect of 1\143-(3-(1-piperidinylmethyl) phenoxy)propyThhydroxyacet-amide 2-hydroxypropane-1, 2, 3-tricarboxylate bismuth (3+) complex (MX1)-MX1. J. Pharm. Pharmacol. (1996) 48:297–301.
   PubMed Web of Science ®Google Scholar
• BESANCON M, SIMON A, SACHS G, SHIN JM: Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J. Biol. Chem. (1997) 272:22438–22446.
   PubMed Web of Science ®Google Scholar
• IWAHI T, SATOH H, NAKAO M: Lansoprazole: a novel benzimidazole protein pump inhibitor and its related compounds have selected activity against Helicobacter pylori. Antimicrob. Agents Chemother. (1991) 35:490–496.
   PubMed Web of Science ®Google Scholar
• SUERBAUM S, LEYING H, KLEMM K, OPFERKUCH W: Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. J. Clin. Microbiol. Infect. Dis. (1991) 10:92–93.
   PubMed Web of Science ®Google Scholar
• FIGURA N, CRABTREE JE, DATTILO M: In-vitro activity of lansoprazole against Helicobacter pylori. J. Antimicrob. Chemother. (1997) 39:585–590.
   PubMed Web of Science ®Google Scholar
• MIDOLO PD, TURNIDGE JD, LAMBERT JR: Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro. J. Antimicrob. Chemother. (1997) 39:331–337.
   PubMed Web of Science ®Google Scholar
• LOU VG, SLERMAN P, MATLOW AG: Helicobacter pylori infection in a paediatric population. In vitro susceptibilities to omeprazole and 8 antimicrobial agents. Antimicrob. Agents Chemother. (1992) 36:1133–1135.
   PubMed Web of Science ®Google Scholar
• SJOSTROM JE, KUHLER T, LARSSON H: Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp. Antimicrob. Agents Chemother. (1997) 41:1797–1801.
   PubMed Web of Science ®Google Scholar
• ERAH PO, GODDARD AF, BARRETT DA, SHAW PN, SPILLER RC: The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. (1997) 39:5–12.
   PubMed Web of Science ®Google Scholar
• BAZZOLI F: Italian omeprazole triple therapy-a 1-week regimen. Scand. J. Gastroenterol. Suppl. (1996) 215:118.
   PubMedGoogle Scholar
• WILLIAMS MP, HAMILTON MR, SERCOMBE JC, POUNDER RE: Seven day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. Aliment. Pharmacol. Ther. (1997) 11:705–710.
   PubMed Web of Science ®Google Scholar
• LAI JY, DE BOER WA, DRIESSEN WM, GEUSKENS LM: Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy. Aliment. Pharmacol. Ther. (1996) 10:645–650.
   PubMed Web of Science ®Google Scholar
• EUROPEAN STUDY GROUP ON ANTIBIOTIC SUSCEPTIBILITY OF HELICOBACTER PYLORI: Results of a multicenter European Survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. (1992) 11:777–781.
   Google Scholar
• VAN DER WOUDEN EJ, VAN ZWET AA, VOSMAER GD et al.: Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands. Emerg. Infect. Dis. (1997) 3:85–89.
   Google Scholar
• VAN ZWET AA, DE BOER WA, SCHNEEBERGER PM et al.: Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands. Eur. J. Clin. Microbiol. Infect. Dis. (1996) 15:861–864.
   PubMed Web of Science ®Google Scholar
• LOPEZ BREA M, DOMINGO D, SANCHEZ I et al.: Metronidazole and clarithromycin susceptibility amongst H. pylori clinical isolates from different Spanish regions. Gut (1996) 39:A13.
   PubMed Web of Science ®Google Scholar
• XIA HX, BUCKLEY M, KEANE CT, O'MORAIN CA: Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J. Antimicrob. Chemother. (1996) 37:473–481.
   PubMed Web of Science ®Google Scholar
• GRAHAM DY, LEW GM, MALATY HM et al.: Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology (1992) 102:493–496.
   PubMed Web of Science ®Google Scholar
• MALFERTHEINER P: Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand. J. Gastroenterol. Suppl. (1993) 196:34–37.
   PubMedGoogle Scholar
• VAIRA D, MENEGATTI M, MIGLIOLI M et al.: Rifaximin suspension for the eradication of Helicobacter pylori. Curr. Ther. Res. (1997) 58:300–308.
   Web of Science ®Google Scholar
• KIMURA K, IDO K, SAIFUKU K et al.: A 1-h topical therapy for the treatment of Helicobacter pylori infection. Am. J. Gastroenterol. (1995) 90:60–63.
   PubMed Web of Science ®Google Scholar
• VON RECKLINGHAUSEN G, DI MAIO C, ANSORG R: Activity of antibiotics and azole antimycotics against Helicobacter pylori. Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis. (1993) 280:279–285.
   Google Scholar
• KUBONOVA K, BENES L, KETTNER M: In vitro activity of pentacaine against Campylobacter pylori. Eur. J. Microbiol. Infect. Dis. (1988) 7: 579.
   PubMedGoogle Scholar
• RAUTELIN H, RENKONEN OV, KOSUNEN TV: In vitro susceptibility of Helicobacter pylori to nitecapone. Eur. J. Clin. Microbiol. Infect. Dis. (1992) 11:274–275.
   PubMed Web of Science ®Google Scholar
• KANE AV, PLAUT AG: Unique susceptibility of Helicobacter pylori to simethicone emulsifiers in alimentary therapeutic agents. Antimicrob. Agents Chemother. (1996) 40:500–502.
   PubMed Web of Science ®Google Scholar
• ANSORG R, VON RECKLINGHAUSEN G, HEINTSCHEL VON HEINEGG E: Susceptibility of Helicobacter pylori to simethicone and other non-antibiotic drugs. J. Antimicrob. Chemother. (1996) 37:45–52.
   PubMedGoogle Scholar
• KONTUREK PC, BRZOZOWSKI T, KONTUREK SI et al.: Studies on the cytoprotective and antisecretory activity of ebrotidine. A review. Arzneimittelforschung (1997) 47:578–589.
   PubMed Web of Science ®Google Scholar
• PALACIN C, TARRAGO C, SACRISTAN A, ORTIZ JA: In vitro anti-Helicobacter pylori activity of ebrotidine. Arzneimittelforschung (1997) 47:471–474.
   PubMed Web of Science ®Google Scholar
• GABRYELEWICZ A, KONTUREK SJ, BUTRUK E et al.: Efficacy and safety of ebrotidine compared with ranitidine in patients with duodenal ulcer. Eur. J. Gastroenterol. Hepatol. (1995) 7:61–66.
   Google Scholar
• KATSURA Y, TOMISHI T, INOUE Y et al.: Anti-Helicobacter pylori agents. 1. 2-(Alkylguanidino)-4-furylthiazoles and related compounds. J. Med. Chem. (1997) 140:2462–2465.
   Google Scholar
• FUJIYAMA K, FUJIOKA T, KODAMA R, NASU M: Effects of E3810, a novel proton pump inhibitor against Helicobacter pylori. Am. J. Gastroenterol. (1994) 89:1371.
   Google Scholar
• HAYAKAWA A, INOUE M, KUNISAKI M, SOSEI M, OKUNO A: Clinical evaluation of Z-103 on gastric ulcers. Yakuri to Chiro (1992) 20:225–264.
   Google Scholar
• KOGA T, KAWADA H, UTSUI Y et al.: In-vitro and in-vivo antibacterial activity of plaunotol, a cytoprotective antiulcer agent, against Helicobacter pylori. J. Antimicrob. Chemother. (1996) 37:919–929.
   PubMed Web of Science ®Google Scholar
• FUKUDA Y, YAMAMOTO I, OKUI-M, TONOKATSU Y, SHIMOYAMA T: Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. J. Clin. Gastroenterol. (1995) 20 (Suppl. 2) :S132–135.
   Google Scholar
• SHIBATA K, ITO Y, HONGO A et al.: Bactericidal activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions. Antimicrob. Agents Chem other. (1995) 39:295–299.
   PubMed Web of Science ®Google Scholar
• •Description of antibacterial activity of a new antiulcer agent.
   Google Scholar
• SHIMOYAMA T, FUKUDA Y, FUKUDA S et al.: Ecabet sodium eradicates Helicobacter pylori infection in gastric ulcer patients. Gastroenterology (1996) 31\(Suppl. 9):59–62.
   Google Scholar
• PIOTROWSKI J, MURTY VL, SLOMIANY A, SLOMIANY BL: Susceptibility of Helicobacter pylori to antimicrobial agents: effect of sulglycotide. Biochem. Mol. Biol. Int. (1995) 35:467–472.
   PubMedGoogle Scholar
• MIDOLO PD, LAMBERT JR, HULL R, LUO F, GRAYSON ML: In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J. Appl. Bacteriol. (1995) 79:475–479.
   PubMedGoogle Scholar
• AL SOMAL N, COLEY KE, MOLAN PC, HANCOCK BM: Susceptibility of Helicobacter pylori to the antibacterial activity of manuka honey. J. Roy. Soc. Med. (1994) 87:9–12.
   PubMed Web of Science ®Google Scholar
• •Report of anti-Helicobacter activity present in a natural product.
   Google Scholar
• SIVAM GP, LAMPE JW, ULNESS B, SWANZY SR, POTTER JD: Helicobacter pylori-in vitro susceptibility to garlic (Allium sativum) extract. Nutr. Cancer (1997) 27:118–121.
   PubMed Web of Science ®Google Scholar
• •Report of anti-Helicobacter activity present in a natural product.
   Google Scholar
• DIKER KS, HASCELIK G: The bactericidal activity of tea against Helicobacter pylori. Lett. Appl. Microbiol. (1994) 19:299–300.
   Web of Science ®Google Scholar
• •Report of anti-Helicobacter activity present in a natural product.
   Google Scholar
• THOMPSON L, COCKAYNE A, SPILLER RC: Inhibitory effect of polyunsaturated fatty acids on the growth of Helicobacter pylori: a possible explanation of the effect of diet on peptic ulceration. Gut (1994) 35:557–561.
   PubMed Web of Science ®Google Scholar
• MARIN-KUAN M, HOUIMEL M, MACH JP et al.: Inhibition of Helicobacter pylori beta ketothiolase by selective peptides. Gut (1998) 43 (Suppl. 2):A6.
   Google Scholar
• FASSBINDER F, ODENBREIT S, KIST M, BERESWELL S: Characterization of the riboflavin synthesis genes ribB, ribC and ribD from Helicobacter pylori. Gut (1998) 43\(Suppl. 2):A8.
   Google Scholar
• PHILLIPS K, MUNSTER DJ, ALLARDYCE RA, BAGSHAW PF: Antibacterial action of the urease inhibitor acetohydroxamic acid on Helicobacter pylori. J. Clin. Pathol. (1993) 46:372–373.
   PubMed Web of Science ®Google Scholar
• PARK JB, IMAMURA L, KOBASHI K: Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol. Pharm. Bull. (1996) 19:182–187.
   PubMed Web of Science ®Google Scholar
• SLOMIANY BL, PIOTROWSKI J, SLOMIANY A: Suppression of Helicobacter pylori urease activity by sucralfate and sulglycotide. Biochem. Mol. Biol. Int. (1997) 42:155–161.
   PubMedGoogle Scholar
• SLOMIANY BL, PIOTROWSKI J, SLOMIANY A: Susceptibility of growth factors to degradation by Helicobacter pylori protease: effect of ebrotidine and sucralfate. Biochem. Mol. Biol. Int. (1996) 40:209–215.
   PubMedGoogle Scholar
• SMOOT DT, EARLINGTON MH, ABEBE E et al.: Effects of sucralfate on vacuolating cytotoxin activity and adherence of Helicobacter pylori to human gastric epithelial cells. J. Assoc. Acad. Minor Phys. (1996) 7:88–92.
   PubMedGoogle Scholar
• PIOTROWSKI J, SLOMIANY A, SLOMIANY BL: Helicobacter pylori lipopolysaccharide inhibition of gastric somatostatin receptor: effect of sucralfate. Biochem. Mol. Biol. Int. (1997) 42:545–551.
   PubMedGoogle Scholar
• PIOTROWSKI J, CZAJKOWSKI A, YOTSUMOTO F, SLOMIANY A, SLOMIANY BL: Sulglycotide effect on the proteolytic and lipolytic activities of Helicobacter pylori toward gastric mucus. Am. J. Gastroenterol. (1994) 89:232–236.
   PubMed Web of Science ®Google Scholar
• MURTY VL, PIOTROWSKI J, MORITA M, SLOMIANY A, SLOMIANY BL: Inhibition of Helicobacter pylori glycosulfatase activity toward gastric sulfomucin by nitecapone. Biochem. Int. (1992) 26:1091–1099.
   PubMedGoogle Scholar
• SALMELA KS, ROINE RP, HOOK NIKANNE J, KOSUNEN TU, SALASPURO M: Effect of bismuth and nitecapone on acet aldehyde production by Helicobacter pylori. Scand. J. Gastroenterol. (1994) 29:528–531.
   PubMed Web of Science ®Google Scholar
• KAMIYA S, OSAKI T, KUMADA J, YAMAGUCHI H, TAGUCHI H: The effect of sofalcone on adherence, production of vacuolating toxin and induction of IL-8 secretion by Helicobacter pylori. J. Clin. Gastroenterol. (1997) 25 (Suppl. 1) :S172–178.
   Google Scholar
• •Report of the anti-adhesive properties of an anti-ulcer agent.
   Google Scholar
• CZAJKOWSKI A, PIOTROWSKI J, YOTSUMOTO F, SLOMIANY A, SLOMIANY BL: Inhibition of Helicobacter pylori colonization by an antiulcer agent, sulglycotide. Biochem. Mol. Biol. Int. (1993) 29:965–971.
   PubMedGoogle Scholar
• •Report of the anti-adhesive properties of an anti-ulcer agent.
   Google Scholar
• HAYASHI S, SUGIYAMA T, YACHI A et al.: Effect of ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells. J. Gastroenterol. (1997) 32:593–597.
   PubMed Web of Science ®Google Scholar
• •Report of the anti-adhesive properties of an anti-ulcer agent.
   Google Scholar
• BITZAN MM, GOLD BD, PHILPOTT DJ et al.: Inhibitors of Helicobacter pylori and Helicobacter mustelae binding to lipid receptors by bovine colostrum. J. Infect. Dis. (1998) 177:955–961.
   PubMed Web of Science ®Google Scholar
• MATHAI E, ARORA A, CAFFERKEY M, KEANE CT, O'MORAIN C: The effect of bile acidson the growth and adherence of Helicobacter pylori. Aliment. Pharmacol. Ther. (1991) 5:653–668.
   PubMed Web of Science ®Google Scholar
• SIMON PM, GOODE PL, MOBASSERI A, ZOPF D: Inhibition of Helicobacter pylori binding to gastrointestinal epithelial cells by acid containing oligosaccharides. Infect. Immun. (1997) 65:750–757.
   PubMed Web of Science ®Google Scholar
• •Report of the inhibition of binding of Helicobacter by the use of complex carbohydrate.
   Google Scholar
• MIDOLO PD, NORTON A, VON ITZSTEIN M, LAMBERT JR: Novel bismuth compounds have in vitro activity against Helicobacter pylori. FEMS Microbiol. Lett. (1997) 157:229–232.
   PubMed Web of Science ®Google Scholar
• LEE A: Vaccination against Helicobacter pylori. J. Gastroenterol. (1996) 31 (Suppl. 9):69–74.
   Google Scholar
• ••An overview of the development of a vaccine for eradication of Helicobacter.
   Google Scholar
• LEE A, O'ROURKE J, DE UNGRIA MC et al.: A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology (1997) 112:1386–1397.
   PubMed Web of Science ®Google Scholar
• KLEANTHOUS H, MYERS GA, GEORGAKOPOULOS KM et al.: Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect. Immun. (1998) 66:2879–2886.
   PubMed Web of Science ®Google Scholar
• •Mucosally-applied antigens enhance protection against infection with Helicobacter.
   Google Scholar
• GOMEZ DUARTE OG, LUCAS B, YAN ZX et al.: Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease A and B. Vaccine (1998) 16:460–471.
   PubMed Web of Science ®Google Scholar
• •Development of novel live vaccine against Helicobacterusing genetically modified Salmonella.
   Google Scholar
• GHIARA P, ROSSI M, MARCHETTI M et al.: Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect. Immun. (1997) 65:4996–5002.
   PubMed Web of Science ®Google Scholar
• BEDWELL J, HOLTON J, VAIRA D, MACROBERT AJ, BOWN SG: In vitro killing of Helicobacter pylori with photodynamic therapy. Lancet (1990) 335:1287.
   PubMed Web of Science ®Google Scholar
• •First report of the action of photodynamic therapy against Helicobacter.
   Google Scholar
• MILSON CE, WILSON M, MACROBERT AJ, BOWN SG: Ex-vivo treatment of gastric Helicobacter infection by photodynamic therapy. J. Photochem. Photobiol. (1996) B32:59-65. Author for correspondence
   Google Scholar